Key result
An ACE inhibitor-based, directly observed thrice-weekly therapy maintained a MAP <107 mm Hg and decreased systolic BP from 122.2 to 116.4 mm Hg compared to prior daily regimens.
Why the study?
Does an ACE inhibitor-based, directly observed thrice-weekly therapy improve blood pressure control and reduce pill burden in hemodialysis patients with hypertension compared to daily therapy?
Does an ACE inhibitor-based, directly observed thrice-weekly therapy improve blood pressure control and reduce pill burden in hemodialysis patients with hypertension compared to daily therapy?
Absolute Event Rate: 116.4% vs 122.2%
Directly observed thrice-weekly antihypertensive therapy after hemodialysis maintains blood pressure control while reducing pill burden and cost compared to daily regimens.
No takes yet. Share an insight, caveat, or question.
May reduce pill burden in dialysis hypertension; leaves open whether TIW directly observed regimens warrant randomized confirmation.
Zheng et al. (2007) studied Hypertension in hemodialysis patients (n=10). ACE inhibitor-based, directly observed thrice-weekly therapy vs. Prior daily antihypertensive prescriptions was evaluated on Systolic blood pressure (mm Hg). An ACE inhibitor-based, directly observed thrice-weekly therapy maintained a MAP <107 mm Hg and decreased systolic BP from 122.2 to 116.4 mm Hg compared to prior daily regimens.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: